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Abstract
Chronic myeloid leukemia (CML) is usually diagnosed in chronic phase, yet there is a small
percentage of patients that is diagnosed in accelerated phase or blast crisis. Due to this
rarity, little is known about the prognosis of these patients. Our aimwas to identify prog-
nostic factors for this cohort.We identified 283 patients in the EUTOS population-based
and out-study registries that were diagnosed in advanced phase. Nearly all patients were
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treated with tyrosine kinase inhibitors. Median survival in this heterogeneous cohort was
8.2 years. When comparing patients with more than 30% blasts to those with 20-29%
blasts, the hazard ratio (HR) was 1.32 (95%-confidence interval (CI): [0.7-2.6]). Patients
with 20-29% blasts had a significantly higher risk than patients with less than 20% blasts
(HR: 2.24, 95%-CI: [1.2-4.0], P = .008).We found that the blast countwas themost impor-
tant prognostic factor; however, age, hemoglobin, basophils and other chromosomal aber-
rations should be considered as well. The ELTS score was able to define two groups (high
risk vs non-high risk) with an HR of 3.01 (95%-CI: [1.81-5.00], P < .001). Regarding the
contrasting definitions of blast crisis, our data clearly supported the 20% cut-off over the
30%cut-off in this cohort. Based on our results, we conclude that a one-phase rather than
a two-phase categorization of de novo advanced phase CML patients is appropriate.
1 | INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disorder char-
acterized by a reciprocal chromosomal translocation resulting in the
BCR-ABL1 fusion gene. The disease is traditionally described in three
distinct clinical phases: chronic phase (CP), accelerated phase (AP) and
blast crisis (BC).1 The exact mechanism that underlies the transforma-
tion from a CP to aggressive BC still remains a key biological question
for the future.2 The accumulation of distinct additional cytogenetic
abnormalities (ACAs)3,4 and a variety of mutations5-7 were associated
with disease progression. Current models of disease progression pre-
dict that increased BCR-ABL1 expression plays an important role in
the secondary molecular and chromosomal changes which precede
disease transformation.8
Although the triphasic course of CML is generally well recognized,
the precise definition of these three phases varies greatly in the
TABLE 1 Staging classification systems for CML
ELN definitions23 WHO definitions33
Chronic phase None of the following criteria
Accelerated phase Any 1 or more of the following hematologic/cytogenetic criteria
Blasts 15-29% in the PB or BM 10-19% in the PB or BM
Blasts + Promyelocytes ≥30% in the PB or BM -
Basophils ≥20% in the PB ≥20% in the PB
Thrombocytes Persistent <100 × 109/L (unrelated to
therapy)
persistent <100 × 109/L (unrelated to
therapy)
persistent ≥1000 × 109/L (unresponsive to
therapy)
White blood cell count - Increasing spleen size and increasing white
blood cell count unresponsive to therapy
Spleen -
Cytogenetic on treatment Major route ACAa any new ACA
at diagnosis - major route ACAa
complex karyotype
abnormalities of 3q26.2
Blast crisis Any one or more of the following hematologic/cytogenetic criteria
Blasts ≥30% in the PB or BM ≥20% in the PB or BM
Extramedullary blast proliferation, apart
from spleen
Extramedullary blast proliferation, apart
from spleen
Large foci or clusters of blasts in the bone
marrow biopsy
Abbreviations: ACA, additional cytogenetic aberrations; BM, bone marrow; ELN, European LeukemiaNet; PB, peripheral blood; WHO, World Health
Organization.
aMajor route ACA: second Ph-chromosome, trisomy 8 or 19, or isochromosome 17q.
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literature.9-11 Staging classification systems most often used in clinical
studies of CML are those from the European Leukemia Net (ELN) and
the World Health Organization (WHO) (Table 1). There is an ongoing
discussion whether the definition of CML-BC should include patients
who have ≥20% blasts (WHO criteria) or ≥30% blasts (ELN criteria).
Furthermore, the presence or absence of cytogenetic or molecular
abnormalities at diagnosis seems to play an important role for future
staging and classification systems of CML.
The vast majority of CML patients are diagnosed in CP. However,
some patients present with advanced phase features at time of diag-
nosis. Their percentage in previous studies varied between 3.1% and
14%.12-16 There is limited information about the clinical characteris-
tics, survival, and prognostic factors of CML patients diagnosed in the
advanced phase of the disease. Kantarjian et al. identified age and
blast count as potential predictors of survival; however, the majority
of patients in that study were from the pre-TKI era.17 Most studies
analyzing prognostic factors and survival outcomes for CML-AP or
-BC refer to patients that developed an AP or BC from initial CP. The
results of these studies indicate that despite the availability of BCR-
ABL1 tyrosine kinase inhibitors (TKIs) the treatment options and the
outcome for these patients are still poor.10,18
As these data suggest that patients diagnosed in the advanced phase
of the disease seem to be a very heterogeneous group in terms of their
prognosis, it is essential to identify characteristics that are predictive for
their outcome. All of the well-established CML prognostic scores like the
Sokal,19 the Euro,20 EUTOS21 or the ELTS score22 were developed and
validated for CML patients in chronic phase. However, whether these
scores are useful to categorize patients who are diagnosed in advanced
phase of CML has not been investigated so far. Therefore, the aim of our
work was to analyze the outcome of patients diagnosed in AP or BC and
to identify prognostic factors associatedwith their survival.
2 | METHODS
2.1 | Definitions
In the registries, accelerated phase and blast crisis were defined
according to the ELN criteria.23 Particularly, the cut-off between AP and
BC was 30% blasts in the blood or bone marrow. Of note, investigators
were asked to provide the disease phase of the patients, but not all vari-
ables involved in the definition of the phases were part of the case report
form. As the registry was to be manageable also for smaller centers in
whole Europe, the data set had to be restricted. Particularly, data on
parameters in bone marrow were not collected. All results with respect
to immature cells reported in this work relate to peripheral blood. Clonal
chromosomal abnormalities in Ph + cells were counted as ACAs. Only
patientswhowere presenting in advanced phasewere considered.
2.2 | Statistical analysis
Correlation between candidate variables was investigated by use of
Spearman's rank correlation coefficient and scatter plots, Mann-
Whitney U test, or Fisher's exact test, whichever was appropriate.
Overall survival was counted from the date of diagnosis. Survival time
of patients alive at the last follow-up was censored. As none of the
patients was (by definition) transplanted in first chronic phase,
patients were not censored at the date of an allogeneic stem cell
transplantation. Survival probabilities were estimated using the
Kaplan-Meier estimator and compared using the log-rank test. For the
multivariate analysis, the Cox proportional hazards model was used.
All P values <.05 were considered significant. Model selection was
done using Akaike's Information Criterion.24 Due to the exploratory
character of this work, no P value adjustment was applied; thus all P-
values have to be interpreted descriptively. An external validation of
these results by another research group would be welcome.
2.3 | Patients
Data in this analysis came from two different sections within the
EUTOS framework. After an update in 2014, the out-study registry
(OSR) contains data of 1545 ‘out-study’ patients who did not partici-
pate in prospective clinical trials but were registered prospectively at
the respective National Study Groups. These patients were diagnosed
between 2002 and 2006. This registry has already been described in
detail.25 The population-based registry (PBR) had the aim to collect all
newly diagnosed patients at the age of 20 and older in certain regions
all over Europe. It covered about 92 million people and the PBR finally
contained data of 2887 CML patients ≥20 years of age. These
patients were registered between January 2008 and December 2012.
The description of the registry can be found elsewhere.26
The PBR comprised data on 188 patients that were diagnosed in
advanced phase.15 In the OSR, we identified 117 patients diagnosed in
advanced phase. For this analysis, we asked for an update of the follow-
up. As a result, three patients had to be excluded due to lacking samples
before start of treatment, and two entries proved to be double records
of the same patient. Also, for six patients no follow-up was available and
for 11 patients, it was not known whether they were in advanced phase
at diagnosis or not. Thus, the final sample size consisted of 283 patients,
of whom 203 were diagnosed in AP and 80 were diagnosed in BC. The
flowchart is given in supplementary Figure 1.
3 | RESULTS
3.1 | Regional distribution
The patients' regional distribution is shown in Table S1. Of note, only
the Czech Republic, Poland, Romania, Russia, Spain, and the United
Kingdom were part of the OSR. In the PBR, all participating countries
except Slovenia contributed at least one patient to the updated
advanced phase data set. In the PBR, either the whole country (for
smaller countries with a population of less than 10 millions) or
selected regions with a maximum of 10 million inhabitants (for larger
countries) were part of the registry.26 Thus, in this study, the number
of patients per country cannot be directly connected to the country's
population. Furthermore, a comparison between countries was not
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possible, as in some countries, the registration was required by law,
while in others, the active participation of the physicians was needed.
3.2 | Baseline values
The sample consisted of 151 male (53%) and 132 female patients
(47%). Median age was 51 years (range: 18-89). The proportion of
patients with transcript type e13a2 only was 53%. Details on the
blood values are recorded in Table 2. We found a weak negative cor-
relation between blast and basophil counts (r = −0.257, P < .001).
When categorizing the patients using the available blast values,
209 (77%) had less than 20% peripheral blasts, 23 (8%) had 20% to
29% blasts, and 39 (14%) had more than 30% blasts at diagnosis. For
the peripheral basophils, 226 patients (84%) had less than 20% baso-
phils and 42 (16%) had 20% or more basophils at diagnosis. From the
267 patients with available blast and basophil values, 167 (63%) had
values below 20% in both parameters. Forty-one patients (15%) had
at least 20% basophils, but less than 20% blasts. Of the patients with
basophils below 20%, 22 patients (8%) had blast values between
20 and 29% and 36 patients (13%) had more than 30% blasts. Only
one patient had more than 30% blasts and more than 20% basophils.
3.3 | Treatment
For the registration in the OSR, treatment with imatinib in the first
6 months from diagnosis was an inclusion criterion. Out of the
179 patients in the PBR, 146 received any TKI (thereof 68 nilotinib or
dasatinib) while 10 patients received only hydroxyurea. Treatment
information was missing for 23 patients. Altogether, 48 patients
underwent allogeneic stem cell transplantation, thereof 20 who were
diagnosed in AP and 28 who were diagnosed in BP.As a sensitivity
analysis, we added the transplant status as a time-dependent covari-
ate to the multiple proportional hazards model and did not find a sig-
nificant effect. Thus, we decided to analyze all patients together.
3.4 | Survival
The median observation time was 5.8 years. Out of 283 patients,
115 died. The median survival time was 8.2 years (95% confidence
interval (CI): [6.3 years - infinity]). We found considerable differences
between patients diagnosed in AP and patients diagnosed in BC. While
median survival was not reached for the patients in AP after a median
observation time of 6.0 years, median survival for the BC patients was
1.8 years (95% CI: [1.2-3.7 years]) (see Figure 1).
Patients with more than 30% blasts had a slightly higher hazard of
dying than patients with 20-29%; the hazard ratio (HR) was 1.32
(95% CI: [0.7-2.6]). Patients with 20-29% had a significantly higher risk
of dying than patients with less than 20% blasts (HR: 2.24, 95% CI:
[1.2-4.0], P = .008). Patients with less than 20% basophils had an inferior
survival compared to the ones with more than 20% basophils, however
this differencewas not significant (HR: 1.55, 95%CI: [0.9-2.8]).
Blasts were prognostically more important for survival. When com-
bining both variables, irrespective of the percentage of basophils, the
median survival time of patients with blast counts <20% was not
reached. In case of <20%basophils, they had a 2-year survival probability
of 0.75 (95% CI: [0.68-0.82]) and of 0.85 (95% CI: [0.75-0.96]) with
TABLE 2 Descriptive statistics and univariate Cox models for mortality
n Median Range HR 95% CI P
Age (years) 283 51 18-89 1.02 1.01-1.04 .001
Hemoglobin (g/dL) 271 9.9 4.4-15.8 0.91 0.83-1.00 .042
WBC (×109/L) 269 119 3-560 1.05 0.90-1.22 .541
Platelets (×109/L) 273 376 9-4005 0.89 0.84-0.94 <.001
Blasts (%) 271 10 0-92 1.02 1.01-1.03 <.001
Basophils (%) 268 4 0-53 0.97 0.95-0.99 .011
Eosinophils (%) 268 3 0-18 0.95 0.90-1.01 .093
Spleen (cm) 269 6 0-40 0.99 0.96-1.01 .334
n % HR 95% CI P
Sex male 151 53% 0.96 0.67-1.38 .825
female 132 47% 1
Type of transcript e13a2 65 53% 1
e14a2 42 34% 0.62 0.33-1.16 .617
e13a2 + e14a2 7 6% 0.63 0.15-2.61 .625
other 8 7% 2.02 0.84-4.88 .117
ACAs yes 54 26% 1.97 1.25-3.09 .003
no 156 74% 1
Extramedullary involvement yes 11 4% 1.75 0.71-4.31 .228
no 272 96% 1
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≥20% basophils. In contrast, the patients with 20-29% blasts had a
median survival of only 3.3 years (2-year survival probability: 0.55, 95%
CI: [0.36-0.82]), while the group with 30% blasts or more had median
survival of only 1.6 years (2-year survival probability: 0.44, 95% CI:
[0.30-0.65]). The Kaplan-Meier survival plots are shown in Figure 2.
Patients with ACAs at diagnosis had a significantly higher hazard
of dying than patients without (HR: 1.97, 95% CI: [1.3-3.1], P = .003).
The presence of a thrombocytopenia (<100 × 109/L) (HR: 2.28, 95%
CI: 1.45-3.58], P < .001) was a further unfavorable prognostic factor.
Univariate analyzes of survival probabilities in dependence on base-
line values are shown in the right part of Table 2. All continuous
covariates were assumed to have a linear effect. However, this assump-
tion is questionable for blast count, where the hazard ratio can only be
interpreted as an “average effect”. It appeared that for small blast values
the increase in the hazard was greater than for larger blast values, thus a
logarithmic transformation would have been more suitable. Important
predictors of survival seemed to be blast count, age, platelets, hemoglo-
bin, basophils, and additional cytogenetic aberrations at diagnosis.
When performing multiple analyzes with the Cox model, we found
blast count, age, hemoglobin, basophils, and ACAs to be important
predictors (Table 3). Blasts was once included as a categorical variable
and once as a continuous variable. Results of the first approach are
given in Table 3. Also, in the multiple model, no significant differences
between the groups 20-29% and >30% were observed, but both
showed significantly worse survival probabilities as compared with
patients with <20% blasts. Using the logarithm of the continuous blast
count instead, we received an HR of 3.07 (95%-CI: [1.86-5.07],
P < .001), while the HRs of the other covariates remained rather simi-
lar. Performing a backward model selection, spleen size, eosinophils,
platelets, leucocytes, basophils, or sex were excluded.
In the next step, we distinguished between patients diagnosed in
AP and patients in BC. For the 141 patients with complete data in AP,
we did a variable selection and found age (HR: 1.02 per year (95%-CI:
[1.00-1.04], P = .033), platelets (HR: 0.999 per increase of 1 × 109/l
(95%-CI: [0.998-1.000], P = .08), hemoglobin (HR: 0.81 per increase of
10 g/dL (95%-CI: [0.69-0.95], P = .010), the presence of ACAs
(HR: 2.06 (95%-CI: [1.03-4.13], P = .042) and the logarithm of the
blast count to be important predictors (HR: 2.96 (95%-CI: [1.23-7.09],
P = .015). In contrast, in case of the 63 patients in BC, only age
(HR: 1.03 (95%-CI: [1.01-1.05], P = .001) and the logarithm of the
blasts (HR: 1.69 (95%-CI: [0.94-3.02], P = .079) were in the final
model. Compared to the model for AP, the impact of the blasts was
smaller, while the hazard ratio of age was almost unchanged.
As a sensitivity analysis, we restricted the analysis data set to the
250 patients where TKI treatment was documented. This analysis
might include a small bias, as patients with a longer survival had a bet-
ter chance to be treated with TKI, yet the results were very similar to
the original ones. The most striking differences were that in the final
model (compared to Table 2) the effect of blasts was even more pro-
nounced. This was with HRs of 2.53 and 2.82 for patients with
20-29% resp. >30% blasts, while in the model for only AP patients,
the age effect was lower (HR: 1.01 per year).
When applying the CML scores established for chronic phase to this
cohort of patients, we got rather distinct results. The Sokal score19 allo-
cated nearly 75% of the patients to the high-risk group and was able to
find a significance between the high-risk and the intermediate-risk group,
F IGURE 1 Survival according to phase at diagnosis
F IGURE 2 Survival according to blasts and basophils. One patient
was observed with ≥30% blasts and ≥20% basophils and is not
shown here
TABLE 3 Multiple Cox model for mortality for 204 patients with
complete data to all variables
HR 95% CI P
Blast 20-29% vs <20% 2.11 1.12-4.00 .022
≥30% vs <20% 2.33 1.33-4.08 .003
ACAs yes vs no 1.55 0.95-2.53 .077
Hemoglobin (g/dL) 0.86 0.78-0.96 .009
Age (years) 1.02 1.01-1.04 .008
Basophils ≥20% vs <20% 0.50 0.22-1.11 .087
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but not between the high-risk and the low-risk group. The Euro score20
did not provide any prognostic discrimination of survival. The EUTOS
score21 was able to identify two different groups; however the high-risk
group had a considerably better survival probability than the low-risk
group. Both in patients with AP as well as with BC, the ELTS score22 was
able to discriminate the high-risk group from the low- and intermediate-
risk groups, but not between low and intermediate risk. In the high-risk
group, 2-year survival probability was 0.65 (95% CI: [0.58-0.72]) as
opposed to 0.88 (95% CI: [0.81-0.95]) in the combined low- and
intermediate-risk (non-high-risk) group (Figure 3). Considering the
182 patients with AP only, 2-year survival probability was 0.76 (95% CI:
[0.68-0.84]) in the high-risk and 0.94 (95% CI: [0.88-0.99]) in the non-
high-risk group (Figure 4). In the 73 patients with BC at diagnosis, the
corresponding results were 0.40 (high-risk group, 95% CI: [0.29-0.56])
and 0.69 (non-high-risk group 95% CI: [0.49-0.96]) (Figure 4). The three
HRswere 3.01 (all patients, 95%-CI: [1.81-5.00], P < .001), 2.79 (patients
with AP, 95%-CI: [1.49-5.25], P = .001), and 2.61 (patients with BC,
95%-CI: [1.10-6.22], P = .030).
4 | DISCUSSION
In this cohort of advanced phase patients, the main objectives were
the description of survival probabilities in patients diagnosed in AP or
BC, and to consider potential prognostic factors related to outcome.
To our knowledge, this study based on data of centers all over Europe
is the first large study on this cohort.
The median survival of the AP patients in the present data was much
better than in patients that developed an AP from a CP. This was reported
in trials from the GIMEMA groupwhere median survival was 37 months,27
from the MD Anderson group with a 4-year survival probability of 53%,17
and from China with a 6-year survival probability of 51%.28 It seems that
patients with de novo AP have a different biological background as com-
pared with patients transferring from CP to AP while under therapy. For
some of the patients here, de novo diagnosis of APmight have been due to
a very late diagnosis of CML, however, without anyone carrying the burden
of a history of resistance to TKI. In contrast to patients that progressed
from CP to AP because they were not responding to TKI, newly diagnosed
patients in APwere reported to show good response when initially treated
with TKI, albeit this was observed in small studies.29,30 In conclusion, AP at
diagnosis should be clearly distinguished fromAP after CP.
Also the survival of patients with de novo diagnosis of BCwas longer
than for patients with a BC that developed during the course of the dis-
ease. After transformation fromCP toBC, median survival in the German
CML-study IV was 7.9 months.31 In a study by the MD Anderson
group,32 median survival for de novo BC patients was more than 2 years,
while median survival for BC patients originally diagnosed in CP or AP
was less than 1 year. In a population-based setting, the Swedish CML
register has recently published a median survival of de novo BC patients
of 1.6 years.30 Even though the differences were smaller than for the AP
patients, transferring results from de novo BC patients to patients that
develop a BC in the course of the disease does not seem appropriate.
Unfortunately, no information on bone marrowwas available, as this
information was not collected within the registries. For this reason, we
refrained from the attempt to combine statistically significant and clini-
cally relevant factors associated with overall survival in a prognostic sys-
tem and to define different risk groups, as was done for the scores
developed for chronic phase patients. To address the need, with the
inclusion of bone marrow parameters, a new blast crisis registry collect-
ing all potentially important prognostic factors has recently been
launched. As an inclusion criterion, the lower limit of 20% blasts in
peripheral blood was established. Allowing for prospective as well as ret-
rospective data, there are reasonable prospects that a proper prognostic
model for the survival of patients diagnosed in BCwill be identified.
In the meantime, the use of well-known scores established for CP
CML patients should be avoided or, at least, handled with caution. All
scores include spleen size, but spleen size did not show a significant
association with survival in the present advanced phase data. For
F IGURE 3 Survival according to ELTS score
F IGURE 4 Survival according to ELTS score and phase at
diagnosis
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basophils, the association of lower values with worse survival is coun-
terintuitive. In correspondence to the findings for these two variables
involved in its definition, outcome predicted by the EUTOS score is
contradictory to medical knowledge and thus of no clinical value. But
after all, like the other scores, the EUTOS score was developed for CP
patients and in addition, for short-term remission outcome. The lack
of a meaningful prognostic result for eosinophils contributed to the
failure of the Euro score. When combining low- and intermediate risk
groups, at least the ELTS score provided a clinically useful discrimina-
tion of overall survival, whether it was in all patients diagnosed in
advanced phase or in the subgroups AP or BC (Figures 3 and 4). Lac-
king a more appropriate prognostic tool, the ELTS score could be
applied until further notice. However, a prognostic score developed in
advanced phase patients remains a desirable aim for the future.
Apart from the lack of data on bone marrow, our patient sample was
subject to further limitations. Data came from two observational regis-
tries where treatment was not standardized, and we expect that the per-
centage of patients treated with second-generation TKI in this cohort
might have increased in the meantime. Besides, the vast differences in
the incidence of CML diagnoses in advanced phases indicate consider-
able heterogeneity between the countries. This heterogeneity could be
due to a more or a less strict application of the criteria defining the
advanced phases, or due to the tendency in a certain country to see a
physician earlier rather than later.With the lack of data on bonemarrow,
it was not possible to verify the phase reported by the investigators for
each of the patients. On the upside, heterogeneity means also strength.
Results do not depend on data from just one study group or even one
single center, but are based on patients from all over Europe supporting
their generalizability. Furthermore, to our knowledge, this is the largest
data set including patients diagnosed in advanced phase.
In this study, the ELN criteria23 were used for the definition of AP
and BC. The most important difference to the WHO criteria is possibly
the discrimination between AP and BC when it comes to the application
of the blasts' cut-off, which is at 30% according to the ELN, but at 20%
according to the WHO criteria.33,34 Discussion about this cut-off is still
ongoing. For patients diagnosed de novo in advanced phase, as a main
finding in this work, univariate andmultiplemodeling results suggest that
at least for blasts in peripheral blood the 20% cut-off is more appropriate.
With the 30% cut-off according to the ELN criteria, survival outcome in
de novo patients defined to be in accelerated phase was quite heteroge-
neous. While advanced phase patients with blasts below 20% showed a
2-year survival probability above 75%, survival probabilities of patients
with 20-29% blasts were significantly worse (55% at 2 years), and much
closer to survival probabilities of patients with ≥30% blasts (44% at
2 years). Hoffmann et al.15 reported a 30-month survival of 84% for
ELTS high risk patients diagnosed in chronic phase in the PBR. Compared
to the survival probability of 75% at 30 months that we had observed in
the group with blasts <20%, there is still a difference. However more
than half of de novo patients with blasts below 20% were responsive to
TKI therapy, and could be considered like late or high-risk chronic phase
patients. It is our perception that a two-phase rather than a three-phase
categorization of de novo patients is appropriate. And, that a 20% blast
cut-off could be involved in a new definition, only discriminating
between chronic phase and blast crisis at diagnosis. As seen in our data,
patients with late chronic phase will be identified as high-risk patients by
the ELTS score and thus, will still receive particular attention by physi-
cians. To achieve a better understanding of CML blast crisis, and to
improve treatments and outcomes, an international blast crisis registry
was launched. It is a major aim of this collaborative project to systemati-
cally collect baseline, treatment and outcome data of patients diagnosed
with CML blast crises. This is to get more information on the biology,
prognosis and treatment of this disease. The registry could also provide
an empirical base for future national and international trials.
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